PBT2 for Middle Ear Infections, page-15

I spoke to Rebecca a couple of weeks back- very friendly lady. She did reiterate to me that right now the company has not set aside any resources for PBT2 and in fact it is currently on ice. The company is focused 100% on ath434 and getting trials started. How much can management take on? Well I’m not sure but given Stamlers salary I hope he’s literally too busy with ath434 to do anything else. If you’re reading this, make no mistake, 434 IS the holy grail for us, hence why approx 55M has been raised solely for this purpose since July 2020.

It’s interesting to see what third parties are doing with PBT2 and I appreciate other posters info on it. However, the hope being instilled in some readers of this forum might breed too much excitement and thus disappointment on pbt2 as radio silence on the compound prevails.

With ATH, time is money given the cash burn rate and so the risk moving into March is no indication of trials starting. I could be wrong to expect this but I would like to see US regulatory authorisation for commencement of trials imminently. It’s been a while since we heard anything from the FDA with regards to the development pathway for 434 trials, which according to the company last October ‘21 was “a robust development program” . If this robustness is a mutual agreement between Ath and the FDA, then when will approval for commencement be received? Given the recent Nz regulatory authorisation, one would hope that other jurisdictions should follow imminently, especially in the US, and get the P2 trial started. I think any indication of the US should boost the SP and de-risk any potential clinical trial delay which IMO could be keeping a lid on the sp at the moment.

Gltah and dyor